Affimed NV (Affimed NV) Dividend Payout Ratio

: 0.00 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Affimed NV's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Affimed NV's Dividend Payout Ratio or its related term are showing as below:

AFMD's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.4
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-04-20), the Dividend Yield % of Affimed NV is 0.00%.

Affimed NV's Dividends per Share for the months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Affimed NV Dividend Payout Ratio Historical Data

The historical data trend for Affimed NV's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Affimed NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Dividend Payout Ratio																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Affimed NV's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Affimed NV Dividend Payout Ratio Distribution

For the Biotechnology industry and Healthcare sector, Affimed NV's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Affimed NV's Dividend Payout Ratio falls into.

Affimed NV Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Affimed NV's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-7.814
	=	N/A

Affimed NV's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-1.626
	=	N/A

Affimed NV (NAS:AFMD) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Affimed NV Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Affimed NV's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Affimed NV (Affimed NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

A28:Germany

Address

Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120

Website

https://www.affimed.com

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.